Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

Neuro-Oncology

Volumn 12, Issue 1, 2010, Pages 14-18

  Mautner, Victor Felix ^a   Nguyen, Rosa ^a   Kutta, Hannes ^a   Fuensterer, Carsten ^b   Bokemeyer, Carsten ^a   Hagel, Christian ^a   Friedrich, Reinhard E ^a   Panse, Jens ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MRI Institute   (Germany)

Author keywords

Bevacizumab; Neurofibromatosis type 2; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; AUDIOMETRY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; EPISTAXIS; FATIGUE; HEARING; HEARING IMPAIRMENT; HUMAN; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUDIOMETRY; HEARING LOSS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; YOUNG ADULT;

EID: 75749140889     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop010     Document Type: Article

References (9)

1. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38:880-885.
2. Otto SR, Brackmann DE, Hitselberger WE, Shannon RV, Kuchta J. Multi-channel auditory brain stem implant: update on performance of 61 patients. J Neurosurg. 2002;96:1063-1071.
3. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation of benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289-294.
4. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumour control, complications, and hearing preservation rates. Neurosurgery. 2007;60:460-468.
5. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008;5:487-491.
6. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706.
7. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol. 2007;83:259-266.
8. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91:329-336.
9. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.